Calvin Cohen

7.5k total citations · 1 hit paper
80 papers, 5.5k citations indexed

About

Calvin Cohen is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Calvin Cohen has authored 80 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Infectious Diseases, 56 papers in Virology and 25 papers in Emergency Medicine. Recurrent topics in Calvin Cohen's work include HIV/AIDS drug development and treatment (67 papers), HIV/AIDS Research and Interventions (57 papers) and HIV Research and Treatment (56 papers). Calvin Cohen is often cited by papers focused on HIV/AIDS drug development and treatment (67 papers), HIV/AIDS Research and Interventions (57 papers) and HIV Research and Treatment (56 papers). Calvin Cohen collaborates with scholars based in United States, United Kingdom and Germany. Calvin Cohen's co-authors include Edwin DeJesus, Jacob Lalezari, Milton C. Weinstein, April D. Kimmel, Elena Losina, Sue J. Goldie, Joseph J. Eron, Charles Farthing, Brian P. Kearney and Andrew Cheng and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Annals of Internal Medicine.

In The Last Decade

Calvin Cohen

77 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 716 citations Jacob Lalezari, Keith Henry et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Calvin Cohen

Since Specialization

Citations

This map shows the geographic impact of Calvin Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Calvin Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Calvin Cohen more than expected).

Fields of papers citing papers by Calvin Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Calvin Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Calvin Cohen. The network helps show where Calvin Cohen may publish in the future.

Co-authorship network of co-authors of Calvin Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Calvin Cohen. A scholar is included among the top collaborators of Calvin Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Calvin Cohen. Calvin Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antiretrovirals and Weight Change: Weighing the Evidence 2024 ·Clinical Infectious Diseases ·David A. Wohl, John R. Koethe, Paul E. Sax, Grace A. McComsey, Daniel R. Kuritzkes, Graeme Moyle, Lee M. Kaplan, Jean van Wyk, Rafael Campo, Calvin Cohen	15
2	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis 2014 ·AIDS Patient Care and STDs ·Georg M. N. Behrens, Bart Rijnders, Mark Nelson, Chloe Orkin, Calvin Cohen, Anthony Mills, Richard Elion, Simon Vanveggel, Marita Stevens, L Rimsky, David Thorpe, (unknown), Kirsten White, Lijie Zhong, (unknown), Susan K. Chuck	23
3	Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV 2013 ·BMJ Open ·Calvin Cohen, Juliana Meyers, Keith L. Davis	101
4	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks 2012 ·The Lancet ·Paul E. Sax, Edwin DeJesus, Anthony Mills, Andrew Zolopa, Calvin Cohen, David A. Wohl, Joel E. Gallant, Hui C. Liu, Lijie Zhong, Kitty Yale, Kirsten White, Brian P. Kearney, Javier Szwarcberg, Erin Quirk, Andrew Cheng	335
5	Cost-Effectiveness of Nucleoside Reverse Transcriptase Inhibitor Pairs in Efavirenz-Based Regimens for Treatment-Naïve Adults with HIV Infection in the United States 2011 ·Value in Health ·Anita J. Brogan, Sandra E. Talbird, Calvin Cohen	9
6	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial 2011 ·The Lancet ·Calvin Cohen, Jaime Andrade‐Villanueva, Bonaventura Clotet, Jan Fourie, Margaret Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, L Rimsky, Simon Vanveggel, Katia Boven	286
7	Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jacob Lalezari, Joseph Gathe, Cynthia Brinson, Melanie Thompson, Calvin Cohen, Edwin DeJesus, (unknown), Jerome Ernst, David E. Martin, (unknown)	56
8	Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and Tenofovir DF (Study COL40263) 2009 ·AIDS Research and Human Retroviruses ·Lisa Ross, Richard Elion, Randall Lanier, Edwin DeJesus, Calvin Cohen, Robert Redfield, Joseph Gathe, (unknown), Linda Yau, (unknown), Belinda Ha	9
9	Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial 2009 ·AIDS ·Calvin Cohen, Daniel S Berger, Gary Blick, (unknown), Dushyantha Jayaweera, Peter Shalit, Melanie Thompson, Monika Peeters, Marie‐Pierre de Béthune, (unknown), (unknown), Brian Woodfall	23
10	Prescribing and using self-injectable antiretrovirals: How concordant are physician and patient perspectives? 2009 ·AIDS Research and Therapy ·Robert Horne, Colin Kovacs, Christine Katlama, Bonaventura Clotet, Carmina R. Fumaz, M Youle, Ranjababu Kulasegaram, Martin Fisher, Calvin Cohen, Jihad Slim, Peter Shalit, Vanessa Cooper, Christos Tsoukas	7
11	Advances in HIV therapeutics: news from the 4th International AIDS Society Conference. 2007 ·PubMed ·(unknown), Richard Elion, Calvin Cohen, Edwin DeJesus, Trevor Hawkins, Graeme Moyle	2
12	T‐1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide‐Containing Treatment Regimen 2005 ·The Journal of Infectious Diseases ·Jacob Lalezari, Nicholaos Bellos, (unknown), Gary Richmond, Calvin Cohen, Robert A. Myers, David H. Henry, Claire Raskino, (unknown), (unknown), Ying Zhang, (unknown), Michael Greenberg, Ralph DeMasi, G. Diego Miralles, (unknown)	78
13	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2003 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	6
14	Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America breakdown → 2003 ·New England Journal of Medicine ·Jacob Lalezari, Keith Henry, Mary O’Hearn, Joan Montaner, Peter J. Piliero, Benoît Trottier, Sharon Walmsley, Calvin Cohen, Daniel R. Kuritzkes, Joseph J. Eron, Jain Chung, Ralph DeMasi, (unknown), (unknown), John Delehanty, Miklos Salgo	716
15	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults 2002 ·AIDS Research and Human Retroviruses ·J Michael Kilby, Jacob Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Roberto C. Arduino, (unknown), Joel E. Gallant, Paul A. Volberding, Robert L. Murphy, Fred Valentine, Michael S. Saag, (unknown), Prakash Sista, Alex Dusek	152
16	The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease 2001 ·New England Journal of Medicine ·Kenneth A. Freedberg, Elena Losina, Milton C. Weinstein, A. David Paltiel, Calvin Cohen, George R. Seage, Donald E. Craven, Hong Zhang, April D. Kimmel, Sue J. Goldie	394
17	Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens 2000 ·Journal of Correctional Health Care ·Calvin Cohen, Peter J. Piliero, (unknown)	1
18	A Randomized Study of the Safety and Antiretroviral Activity of Hydroxyurea Combined with Didanosine in Persons Infected with Human Immunodeficiency Virus Type 1 2000 ·The Journal of Infectious Diseases ·James Hellinger, Marika K. Iwane, Jeffery J. Smith, A. Fleishman, Ramón A. Torres, Shannon Schrader, George Perez, Calvin Cohen, Gail Skowron, (unknown), (unknown), Ellen C. Cooper, Kevin R. Frost	18
19	Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease 1998 ·The Lancet ·D. William Cameron, Margo Heath‐Chiozzi, Sven A. Danner, Calvin Cohen, Stephen Kravcik, Clement Maurath, Eugene Sun, David Henry, Richard A. Rode, (unknown), John M. Leonard	427
20	Question and Answer Session 1998 ·AIDS Patient Care and STDs ·Kevin R. Frost, Paul Bellman, Calvin Cohen, Judith S. Currier, Jay F. Dobkin, Wafaa El‐Sadr, Mark Holodniy, (unknown), (unknown), Laura Pinsky, (unknown), Anita Vaughn, Michael S. Saag	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact